Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
|1||ChiCTR1900027147||2020-01-01||2019-11-02||Efficacy and safety of adalimumab in Behcet's disease-related uveitis||Efficacy and safety of adalimumab in Behcet's disease-related uveitis||Behcet's disease-related uveitis||1:Adalimumab;||State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University||NULL||Pending||Both||1:30;||Phase 4||China|
|2||JPRN-UMIN000012469||2013/12/02||02/12/2013||Comparison of Adalimumab and Steroid in Intestinal Behcet's disease||Comparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study||Intestinal Behcet's disease||Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously.|
Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately
|Castle Study Group||NULL||Recruiting||15years-old||Not applicable||Male and Female||50||Not selected||Japan|
|October 2010||17/11/2010||A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease||A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease||Intestinal Behçet's Disease||Biological: Adalimumab||AbbVie (prior sponsor, Abbott)||Eisai Co., Ltd.||Completed||15 Years||N/A||All||20||Phase 3||Japan|